에 대한 최신 뉴스 Grifols (NASDAQ:GRFS) 주식

Grifols

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

Mid Cap

News

Movers

CRDO

GRFS

LCID

NUVL

PRCT

다음은 지난주 큰 폭의 상승세를 보인 8개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 1. 루시드 그룹(NASDAQ:LCID)의 주식이 32.91% 급등했다. 이 회사는 루시드 파이낸셜 서비시스(Lucid Financial Services)가 캐나다의 다양한 금융 옵션에 임대를 추가했다고 발표했다. 경제와 금리 인하에 대한 파월 의장의 발언도 심리를 개선했다. 

루시드 및 그리폴스는 지난주 최고 성과를 보여준 8개 중형주 중 일부 (8월 18일-8월 24일)

Grifols, S.A. - American Depositary Shares

Grifols SA

WIIM

Grifols shares are trading higher following a report suggesting banks are preparing to submit final offers for a buyout debt deal.

<a href="https://www.bloomberg.com/news/articles/2024-11-14/banks-to-pitch-roughly-11-billion-buyout-debt-deal-for-grifols">https://www.bloomberg.com/news/articles/2024-11-14/banks-to-pitch-roughly-11-billion-buyout-debt-deal-for-grifols</a>
Banks are getting ready to submit final offers to Brookfield Asset Management for a debt package of about €11 billion ($11.6 billion) to back the take-private of Spanish pharmaceutical producer Grifols SA.

Reported Earlier, 'Banks To Pitch Roughly €11 Billion Buyout Debt For Grifols; Lenders Expected To Submit Best And Final Offers Next Week; Takeover Deal Likely To Rank Among Biggest In Europe This Year' - Bloomberg News

Mason Capital Criticizes Grifols Board For Governance Failures And Shareholder Value Loss; Calls For Independent Directors And Improved Oversight; Claims Brookfield Transaction Undervalues Grifols

Grifols shares are trading higher following a report suggesting Brookfield is seeking information on the company's related-party deals and that it is confident it can line up financing

Financing

Brookfield Is Said To Seek Info On Grifols Related-Party Deals; Said To Be Confident It Can Line Up Financing

Grifols shares are trading higher after the company announced it received FDA approval to treat surgical bleeding in pediatric patients with its fibrin sealant solution.

<ul>
<li>Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasis</li>
<li>Grifols surgical bleeding management treatments form part of an increasingly robust portfolio of innovative therapeutics enhancing the health and well-being of patients &nbsp;</li>
</ul>
BARCELONA, Spain, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:<a href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced that its plasma-protein based fibrin sealant (FS) for controlling surgical bleeding has received approval from the United States Food and Drug Administration (FDA) for pediatric patients.
The U.S. indication for children and adolescents extends the availability of FS, which is already approved for this patient segment in Europe, in addition to adults. During surgery Grifols FS promotes hemostasis and tissue sealing, resulting in reduced blood loss and potentially fewer complications.
Grifols FS biosurgery treatment is commercialized as VISTASEAL&#x2122; in the U.S. and Canada, and VERASEAL&#x2122; in Europe and elsewhere. Both brands are marketed and distributed by Johnson &amp; Johnson MedTech, as part of a strategic collaboration between the two companies announced in 2019.
Grifols FS combines two plasma proteins, fibrinogen and thrombin, and is applied with Johnson &amp; Johnson MedTech's airless spray technology to rapidly form clots. The FS solution is now available in 18 countries.

Biotech

General

Grifols Receives FDA Approval To Treat Surgical Bleeding In Pediatric Patients With Its Fibrin Sealant Solution

Success Could Lead To FDA Approval For One Of The First Treatments For Chemical Warfare Ocular Damage, Phase 2 Trial For Dry Eye Disease Planned For 2025

Grifols Partners With BARDA For Testing Ocular Immunoglobulin Eye Drops As Treatment For Sulfur Mustard-Induced Eye Injury

The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs &nbsp;
GigaGen's recombinant polyclonals are part of Grifols' robust innovation strategy and commitment to delivering the next generation of antibody drugs for patients and healthcare professionals
SAN CARLOS, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LYus6vr6e9kkAq1UFdnEMG_rFiPgb3buMnD1EXp_OmcSohXze17gw6aPoLbrltGSuEs4Oj_YBED1OsQ6UqvuXoA04Rxz2r_79ReiInhcuExlX32QTGd56a2BjByK0lEV2Auzdzx-M99lVVQrUqndKj7GNY6lCKL-oJM-GlHGcFWg5kTjkN3KgKGyDst1XAKO">GigaGen Inc.</a>, a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint-resistant cancers, and a subsidiary of <a href="https://www.globenewswire.com/Tracker?data=xsHSTMVkJs06-0kEN0wfCEXi2BXZZz3aZPpT4p5W8XMG2hSTSIHgnvK74MzZpn-TkPKjm6mxkYHbFBWQt1hzfA==">Grifols</a>, announced today that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The award, valued at up to $135.2 million, is to develop a recombinant polyclonal antibody therapy for botulinum neurotoxins (BoNT) and a second biothreat of interest to the agency that will be determined at a later time.

Contracts

GigaGen Awarded U.S. BARDA Contract Valued Up To $135.2M To Develop Recombinant Polyclonal Antibody Therapies For Botulinum Neurotoxins And An Additional Biothreat

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Tuesday.
Shares of Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) fell in today's pre-market trading after the company announced a <a href="https://www.benzinga.com/news/24/09/40991747/snowflake-stock-dips-on-offering-after-hours-what-to-know">$2 billion private placement of senior convertible notes.</a>
Snowflake announced it intends to offer $1 billion aggregate principal amount of its convertible senior notes due 2027 and a $1 billion aggregate principal amount of its convertible senior notes due 2029.
Snowflake shares fell 3.3% to $109.56 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Light &amp; Wonder, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>) shares tumbled 17.1% to $93.43 in pre-market trading after the company received an order from the U.S. District Court for the District of Nevada granting Aristocrat a preliminary injunction relating to L&amp;W&#8217;s Dragon Train game..</li>
<li>Hawaiian Electric Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HE#NASDAQ">HE</a>) shares fell 10.5% to $9.75 in pre-market trading. Hawaiian Electric Industries raised $500 million via secondary stock offering of 54 million shares at $9.25 per share.</li>
<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) fell 5.8% to $2.34 in pre-market trading. Uxin shares jumped 54% on Monday after the company reported a year-over-year increase in first-quarter sales results.</li>
<li>argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) shares declined 3.3% to $511.19 in pre-market trading.</li>
<li>Universal Stainless &amp; Alloy Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAP#NASDAQ">USAP</a>) fell 2.4% to $39.10 in pre-market trading.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares fell 2.4% to $8.59 in pre-market trading.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/markets/24/09/40991631/jim-cramer-says-this-utilities-stock-is-a-buy-we-need-cheap-power"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40991631/jim-cramer-says-this-utilities-stock-is-a-buy-we-need-cheap-power">Jim Cramer Says This Utilities Stock Is A Buy: &#8216;We Need Cheap Power&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

ARGX

SNOW

USAP

UXIN

Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Rumors

Brookfield In Talks With Sovereign Funds To Join Grifols Bid

These eight mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) shares soared 32.91%. The company announced that Lucid Financial Services has added leasing to its range of <a href="https://www.benzinga.com//node/40466130" target="_blank" rel="noreferrer noopener">financing options in Canada</a>. Fed Chair Powell&#8217;s comments about the economy and interest rate cuts also improved the sentiment.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) stock rose 32.04% after it reported second-<a href="https://www.benzinga.com//node/40487035" target="_blank" rel="noreferrer noopener">quarter financial results</a>.</li>
<li>PROCEPT BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) shares escalated 22.67% after the company announced FDA 510(k) clearance of <a href="https://www.benzinga.com//node/40481411" target="_blank" rel="noreferrer noopener">its HYDROS Robotic system</a>.</li>
<li>Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) shares were up 20.02%.</li>
<li>Evolent Health, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock upped 19.98% following a report suggesting <a href="https://www.benzinga.com//node/40529349" target="_blank" rel="noreferrer noopener">the company is exploring a sale</a>.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares jumped 19.50% following a report suggesting that Brookfield Asset Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) is seeking debt financing to acquire the company.</li>
<li>Nuvalent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>) stock increased 19.33%.</li>
<li>Amer Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) stock escalated 16.60% after it reported better-than-expected second-quarter <a href="https://www.benzinga.com//node/40466836" target="_blank" rel="noreferrer noopener">results and raised its FY24 EPS outlook</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40543876/zoom-video-microstrategy-and-target-were-among-top-11-large-cap-gainers-last-week-aug-18-aug-24-ar" target="_blank" rel="noreferrer noopener">Zoom Video, MicroStrategy And Target Were Among Top 11 Large Cap Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40543907/snowflake-jd-com-and-temu-parent-pdd-are-among-top-8-large-cap-losers-last-week-aug-18-aug-24-are-" target="_blank" rel="noreferrer noopener">Snowflake, JD.com And Temu Parent PDD Are Among Top 8 Large Cap Losers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Lucid, Grifols And Amer Sports Are Among Top 8 Mid Cap Stock Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Thursday.
Shares of Zoom Video Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) rose sharply during Thursday's session following <a href="https://www.benzinga.com/news/earnings/24/08/40495102/zoom-video-reports-better-than-expected-q2-results-strong-forward-guidance-details">better-than-expected reported second-quarter financial results.</a>
Zoom reported quarterly earnings of $1.39 per share which beat the analyst consensus estimate of $1.21 by 14.88%. Quarterly revenue of $1.16 billion also beat the consensus estimate and is a 2.09% increase from the same period last year.
Zoom Video shares jumped 12.2% to $67.62 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Peloton Interactive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) shares jumped 27% to $4.27 after reporting better-than-expected second-quarter financial results.</li>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) gained 21% to $10.70 after the company announced a partnership with ePages.</li>
<li>Opera Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>) rose 16.7% to 14.99 after the company reported better-than-expected second-quarter financial results. Also, the company issued FY24 revenue guidance above estimates.</li>
<li>EHang Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) gained 14.6% to $14.30 after the company reported better-than-expected second-quarter financial results.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) rose 11.5% to $8.55.</li>
<li>Olaplex Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) rose 11.4% to $2.44.</li>
<li>Calumet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) gained 11.4% to $19.53.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) gained 10.2% to $14.89.</li>
<li>OSI Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSIS#NASDAQ">OSIS</a>) rose 8.6% to $157.00 after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance above estimates.</li>
<li>Lindblad Expeditions Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIND#NASDAQ">LIND</a>) gained 8.6% to $8.93.</li>
<li>Opendoor Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) rose 8.5% to $2.18.</li>
<li>Redfin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) rose 7% to $9.66.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) gained 4.7% to $16.14.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40506247/ibm-is-doing-a-great-job-jim-cramer-says-but-dont-buy-this-real-estate-stock">IBM Is Doing A &#8216;Great Job,&#8217; Jim Cramer Says — But Don&#8217;t Buy This Real Estate Stock</a></li>
</ul>

Intraday Update

CLMT

LIND

MNSO

OLPX

OPEN

OPRA

OSIS

PTON

RDFN

RZLV

Zoom Video Posts Strong Q2 Results, Joins Peloton Interactive, Opera And Other Big Stocks Moving Higher On Thursday

Grifols shares are trading higher after reports that Brookfield is seeking debt financing to acquire the company.

Brookfield Reportedly In Talks With Banks Including UBS And Bank Of America To Fund Grifols Takeover Bid

Brookfield Asset Management is reportedly seeking 9.5 billion euros ($10.6 billion) in debt financing for a potential take-private deal for Grifols SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>), a Spanish <a href="https://www.benzinga.com/general/health-care">pharmaceutical company.</a>
In a July regulatory filing, Grifols said that Brookfield Capital has confirmed that it has engaged in preliminary discussions with Grifols&#8217;s key shareholders regarding a potential joint offer to delist the company&#8217;s shares from the Spanish stock <a href="https://www.benzinga.com/general/biotech/24/07/39669365/beleaguered-spanish-drug-firm-grifols-stock-jumps-on-monday-heres-why" target="_blank" rel="noreferrer noopener">exchanges and NASDAQ</a>.
The investment firm has approached banks to secure funding to refinance Grifols&#8217; existing debt, which includes loans and high-yield bonds.
The move could result in significant financial restructuring, with participating banks committing to the initial financing before distributing it to investors.
The Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-08-21/brookfield-seeks-close-to-10-billion-debt-for-grifols-takeover?srnd=homepage-Europe" rel="noreferrer noopener">report</a> notes that the deal could be critical for Grifols, as it might trigger a clause that allows bondholders to demand repayment at a premium—significantly higher than current trading levels for some of its bonds.
The prospect of the acquisition led to a notable market response, with Grifols&#8217; 2028 bonds gaining over 6 cents to nearly 94 cents on the euro and the company&#8217;s shares rising by as much as 6.4% in Madrid.
The report notes that if the deal is finalized, it marks one of the largest takeovers of a publicly traded European company since 2022.
However, Brookfield&#8217;s ability to increase Grifols&#8217; debt is limited, given that the company has been scrutinized for its leverage levels.
Three agencies downgraded Grifols&#8217; credit rating this year, culminating in Moody&#8217;s Ratings <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37717622/grifols-gets-downgraded-fitch-s-p-flag-cash-flow-concerns-at-pharma-company" rel="noreferrer noopener">discontinuing coverage in July</a>.
In March, a new&nbsp;report by Gotham City Research questioned the company&#8217;s &#8220;transparency, integrity <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37517028/spanish-healthcare-firm-grifols-hit-with-new-gotham-citys-short-report-faces-questions-regarding-" rel="noreferrer noopener">and ethical conduct</a>.&#8221;
As per its February SEC <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1438569/000110465924025280/tm246711d1_6k.htm" rel="noreferrer noopener">filing</a>, Grifols had previously denied Gotham City&#8217;s accusations, saying it had already replied to all of the questions raised in the latter&#8217;s reports.
In January, the European Central Bank initiated inquiries into several lenders, urging them to disclose their exposure to&nbsp;Grifols&nbsp;and its affiliated entities following Gotham City Research&#8217;s accusations <a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36675593/spanish-healthcare-firm-grifols-reputational-damage-and-debt-woes-european-central-bank-probes-le" rel="noreferrer noopener">of financial manipulation</a>.&nbsp;
Price Action: GRFS stock is up 10.2% at $7.92 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40484046/macys-q2-earnings-revenue-miss-points-to-challenging-environment-cuts-2024-forecast" target="_blank" rel="noreferrer noopener">Macy&#8217;s Q2 Earnings: Revenue Miss, Points To &#8216;Challenging&#8217; Environment, Cuts 2024 Forecast</a>.</li>
</ul>
Photo: Shutterstock

Health Care

Brookfield Negotiates Over $10B In Debt Financing For Acquisition Of Spanish Pharma Giant Grifols

GIGA-2339 is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic hepatitis B virus (HBV) infection; trial initiation expected in Q4 2024
Containing more than 1,000 fully human recombinant anti-HBV antibodies, GIGA-2339 reproduces the human body's natural immune response
GigaGen's recombinant polyclonals are part of Grifols' robust innovation strategy and commitment to delivering the next generation of antibody drugs for patients and healthcare professionals
SAN CARLOS, Calif. , July 31, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=iDGUPDDlHYtTOJbjoG8uFqxk646ASiqUJn2t_fFBuUjR37u_0tPhsugtRvNWSzceXG1bzwH0np-wYiUHDkzXr5MDlE1siWMvqitvz9XxVVmtiBVOCohO6fEsK8PLSr7KKNiDwUa-keJWQB_-tbpNu50li2ZB2i_Es5ikCaXxNQPyBUE09WkmHsUfYr0bsh94">GigaGen Inc.</a>, a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of <a href="https://www.globenewswire.com/Tracker?data=tN9swu9LAmdftJQuKrzEZUuj47NJRd0UmOhHjX8aNkmQbG6v7jmhtDmXKqAOIQ5wmw9IhwNFezhc_MM_N1TDGw==">Grifols</a>, announced today that the United States Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 1 trial to evaluate the company's first recombinant polyclonal drug for the treatment of hepatitis B virus (HBV) infection, GIGA-2339.

Grifols' GigaGen Receives FDA Clearance Of IND Application For Phase 1 Trial Of Recombinant Polyclonal For HBV Treatment, GIGA-2339

<a href="https://www.bloomberg.com/news/articles/2024-07-30/grifols-new-auditor-finds-non-cash-accounting-discrepancy-linked-to-china-stake">https://www.bloomberg.com/news/articles/2024-07-30/grifols-new-auditor-finds-non-cash-accounting-discrepancy-linked-to-china-stake</a>
Spain's <a href="https://www.bloomberg.com/quote/GRF:SM">Grifols SA</a> is set to report an unexpected accounting adjustment related to its stake in <a href="https://www.bloomberg.com/quote/002252:CH">Shanghai RAAS</a>, according to a person familiar with the matter.
The company recorded €400 million ($433 million) more than it should have for the value of an asset owned by the Chinese firm, the person said, asking not to be named discussing private information. The adjustment, set to be announced as soon as Tuesday, will not affect Grifols' profit and loss statement, the person said.

Global

"Grifols' New Auditor Discovers Non-Cash Accounting Discrepancy Linked To China Stake; Spanish Company To Report Adjustment Related To China Stake; Discrepancy In Reserves Accounting Found By Auditor Deloitte" - Bloomberg News

FDA Approves Expanded Label For Grifols' XEMBIFY, The First 20% SCIg For Treatment-Naïve Patients With Primary Humoral Immunodeficiencies; Approval Includes Biweekly Dosing Following Positive Phase 4 Data, Enhancing Flexibility And Convenience For Patients

Grifols Board Votes To Grant Brookfield Access To Information For Potential Takeover Bid; Establishes Independent Committee To Monitor Transaction Progress And Present Proposals To Board

Berenberg lowered the firm's price target on Grifols (GRFS) to EUR 15.50 from EUR 15.60 and keeps a Buy rating on the shares. Published first on Th...

Grifols price target lowered to EUR 15.50 from EUR 15.60 at Berenberg

Brookfield Asset Management (BAM) is awaiting information from Grifols (GRFS) about related-party transactions as it seeks to complete its due dili...

Brookfield awaiting information for potential Grifols bid, Bloomberg says

12:02 EST Brookfield still pursuing Grifols (GRFS) deal, Bloomberg reports Published first on TheFly – the ultimate source for real-time, market-mo...

Brookfield still pursuing Grifols deal, Bloomberg reports

Grifols gains after report Brookfield still pursuing possible takeover

Rahul Srinivasan, Chief Financial Officer, said "This record-breaking quarter stands as a testament to the passion and commitment of our entire tea...

Grifols reaffirms FY24 guidance

Revenue increased by 12.4% in constant currencty to EUR 1.793B for the third quarter and adjusted EBITDA in Q3 grew by 26.7% cc to EUR 462M. Nacho ...

Grifols reports Q3 adjusted EBITDA of EUR 462M, up 26.7% in constant currency

Mason Capital Management, a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols (GRFS) class A shares, sent a...

Grifols holder Mason Capital opposes potential transaction, tells board

Grifols holder Mason Capital against potential Brookfield deal

Deutsche Bank raised the firm's price target on Grifols (GRFS) to EUR 10 from EUR 9 and keeps a Hold rating on the shares. Published first on TheFl...

Grifols price target raised to EUR 10 from EUR 9 at Deutsche Bank

Grifols spikes as banks reportedly finalize offers for buyout debt deal

Press Releases

Grifols' Biotest receives FDA approval for innovative Yimmugo® immunoglobulin  to treat primary immunodeficiencies

Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group

Grifols' Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years

Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients

GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339

Grifols S.A. (GRFS) Admits Improper Accounting, Announces Restatements, Shares Decline Again – Hagens Berman

GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat

Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury

Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Arcellx

ADMA Biologics

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biohaven

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Nuvalent

Vaxcyte

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Viking Therapeutics

JP Morgan

다음은 지난주 큰 폭의 상승세를 보인 8개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
1. 루시드 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>)의 주식이 32.91% 급등했다. 이 회사는 루시드 파이낸셜 서비시스(Lucid Financial Services)가 <a href="https://www.benzinga.com//node/40466130" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">캐나다의 다양한 금융 옵션</a>에 임대를 추가했다고 발표했다. 경제와 금리 인하에 대한 파월 의장의 발언도 심리를 개선했다.
2. GDS 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>)가 <a href="https://www.benzinga.com//node/40487035" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2분기 재무 결과</a>를 보고한 후 주가는 32.04% 상승했다.
3. 프로셉트 바이오로보틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>)가 <a href="https://www.benzinga.com/pressreleases/24/08/g40481411/procept-biorobotics-announces-fda-clearance-of-the-hydros-robotic-system-the-next-generation-ai-po" target="_blank" rel="noopener">자사의 하이드로스 로보틱(HYDROS Robotic) 시스템</a>에 대한 FDA 510(k) 승인을 발표한 후 주가는 22.67% 상승했다.
4. 크레도 테크놀로지 그룹 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>)의 주식이 20.02% 상승했다.
5. 에볼런트 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>)가 <a href="https://www.benzinga.com//node/40529349" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">매각을 모색하고</a> 있다는 보고서가 나온 후 주가는 19.98% 상승했다.
6. 그리폴스 S.A.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) 주식이 19.50% 급등했다. 이는 브룩필드 에셋 매니지먼트(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/bam" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BAM" data-google-interstitial="false">BAM</a>)가 회사를 인수하기 위해 부채 자금을 모색하고 있다는 보도가 나온 후 발생한 일이다.
7. 뉴발런트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>)의 주식이 19.33% 상승했다.
8. 에이머 스포츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>)가 예상보다 나은 2분기 <a href="https://www.benzinga.com//node/40466836" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">실적을 보고하고 FY24 EPS 전망을 상향</a> 조정한 후 주식이 16.60% 급등했다.
추가로 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%a4%8c-%eb%b9%84%eb%94%94%ec%98%a4-%eb%b0%8f-%ed%83%80%ea%b9%83%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%97%ac%ec%a4%80-11%ea%b0%9c-%eb%8c%80/" target="_blank" rel="noopener">줌 비디오 및 타깃은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (8월 18일-8월 24일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%8a%a4%eb%85%b8%ec%9a%b0%ed%94%8c%eb%a0%88%ec%9d%b4%ed%81%ac-%eb%b0%8f-jd%eb%8b%b7%ec%bb%b4-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-8/" target="_blank" rel="noopener">스노우플레이크 및 JD닷컴 지난주 최악의 성과를 보인 8개 대형주 중 일부 (8월 18일-8월 24일)</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Grifols

뉴스

에 대한 최신 뉴스 Grifols (NASDAQ:GRFS) 주식

일요일, 8월 25, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌